Fintel reports that on November 1, 2023, William Blair initiated coverage of Eyenovia (NASDAQ:EYEN) with a Outperform recommendation.
Analyst Price Forecast Suggests 743.97% Upside
As of November 1, 2023, the average one-year price target for Eyenovia is 11.90. The forecasts range from a low of 8.08 to a high of $15.75. The average price target represents an increase of 743.97% from its latest reported closing price of 1.41.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Eyenovia is 10MM, an increase of 3.88%. The projected annual non-GAAP EPS is -0.90.
What is the Fund Sentiment?
There are 115 funds or institutions reporting positions in Eyenovia. This is an increase of 65 owner(s) or 130.00% in the last quarter. Average portfolio weight of all funds dedicated to EYEN is 0.02%, a decrease of 76.50%. Total shares owned by institutions increased in the last three months by 76.40% to 6,850K shares. 
The put/call ratio of EYEN is 0.08, indicating a bullish outlook.
What are Other Shareholders Doing?
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 707K shares representing 1.67% ownership of the company. In it's prior filing, the firm reported owning 617K shares, representing an increase of 12.72%. The firm decreased its portfolio allocation in EYEN by 29.02% over the last quarter.
Geode Capital Management holds 555K shares representing 1.31% ownership of the company. In it's prior filing, the firm reported owning 260K shares, representing an increase of 53.18%. The firm increased its portfolio allocation in EYEN by 29.77% over the last quarter.
Lasry Marc holds 548K shares representing 1.29% ownership of the company. No change in the last quarter.
IWM - iShares Russell 2000 ETF holds 547K shares representing 1.29% ownership of the company.
Renaissance Technologies holds 427K shares representing 1.01% ownership of the company. In it's prior filing, the firm reported owning 262K shares, representing an increase of 38.61%. The firm increased its portfolio allocation in EYEN by 18.81% over the last quarter.
Eyenovia Background Information
(This description is provided by the company.)
Eyenovia, Inc. is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
